Needham & Company Remains Bullish on Omeros (OMER) Following Mixed 3Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall St slips as higher yields offset upbeat corporate earnings
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Boeing reports first revenue drop in 7 quarters as deliveries decline
- Oil prices fall as U.S. business activity cools, concerns over Middle East ease
- Yen on the brink, but Tesla pulls back
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Hasbro (HAS) brand strength sees earnings top expectations
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
Omeros Corporation Reports Third Quarter 2016 Financial Results
November 9, 2016 4:02 PM EST-- Conference Call Today at 4:30 p.m. ET --
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2016, which include:
3Q 2016 total and OMIDRIA® revenues were $11.3 million. Revenues from OMIDRIA sales rose 248% from the prior year quarter and 13% from 2Q 2016. OMIDRIA units sold by... More
